Eli Lilly's retatrutide and GLP‑1 weight‑loss drugs reshape obesity treatment

Eli Lilly's experimental drug retatrutide has shown greater weight‑loss results than existing GLP‑1 medicines such as Ozempic and Wegovy in early trials. The compound, still in clinical development, could expand therapeutic options for obesity and related metabolic disorders if regulatory approval is secured.

A separate study of U.S. women who began GLP‑1 treatment found that an average 8.6% loss of body weight was linked to a 13‑point rise in employment rates and an 18‑point increase in the likelihood of marriage or cohabitation, especially for those previously unemployed or single. The researchers concluded that the benefits stem from reduced first‑impression bias rather than improved personal well‑being, noting that participants reported no rise in life satisfaction or mental health.